Table 1. Characteristics of the study population.
| Total | Statin Use | No Statin Use | ||
| Category | Subcategory | N = 1538 | N = 238 | N = 1300 |
| Age (median years) | 43 (36–49) | 46 (40–53) | 42 (36–47)** | |
| Sex | Male | 1034 (67.2%) | 172 (72.3%) | 862 (66.3%) |
| Female | 504 (32.7%) | 66 (27.7%) | 438 (33.7%) | |
| Race | Black | 1112 (72.3%) | 138 (58.0%) | 974 (74.9%)** |
| White | 292 (22.5%) | 92 (38.7%) | 292 (22.5%)** | |
| Other | 40 (2.7%) | 8 (3.4%) | 34 (2.6%) | |
| HIV Risk Group1 | IDU | 551 (34.3%) | 48 (20.2%) | 503 (38.7%)** |
| MSM | 445 (28.9%) | 91 (38.2%) | 354(27.2%)** | |
| Heterosexual Contact | 791 (51.7%) | 106 (44.5%) | 685 (52.7%)* | |
| CD4 (median cells/mm3) | 225 (80–358) | 270 (153–461) | 200 (70–339)** | |
| HIV-1 RNA (median copies/ml) | 36,186 (1,633–145,950) | 11,149 (88–126,816) | 39,879 (3,252–163,006)** | |
| Hemoglobin (median g/dL) | 12.7 (11.3–14.1) | 13.2 (12.0–14.6) | 12.7 (11.3–14.0)** | |
| Total cholesterol (median mg/dL) | 166 (141–194) | 196 (168–238) | 160 (134–188)** | |
| Antihypertensive Use | 407 (29.3%) | 114 (46.3%) | 293 (25.6%)** | |
| Prior ART | 933 (60.7%) | 176 (73.9%) | 757 (58.2%)** | |
| Prior ADI | 720 (46.8%) | 132 (55.4%) | 588 (45.2%)** | |
| Viral hepatitis C co-infection | 537 (34.9%) | 61 (25.6%) | 476 (36.6%)** | |
| Year HAART started | < 2004 | 875 (56.9%) | 159 (66.8%) | 716 (55.1%)** |
| ≥2004 | 663 (43.1%) | 79 (33.2%) | 584 (44.9%) |
*0.01 < p-value < 0.5.
**p-value < 0.01.
1
Categories are not mutually exclusive.